8-K: Celularity Inc. Faces Nasdaq Delisting Risk After Failing to File Annual Report

Celularity Inc. received a notice from Nasdaq for failing to file its 2023 annual report on time, putting its listing status at risk.

Summary

• Celularity Inc. did not file its 2023 Form 10-K annual report by the extended deadline of April 15, 2024.
• The company informed Nasdaq on April 17, 2024, that it had not completed the preparation of its financial statements for the year ended December 31, 2023.
• Nasdaq issued a formal notice on April 17, 2024, stating that Celularity is not in compliance with the timely filing requirements of Nasdaq Listing Rule 5250(c)(1).
• Celularity's common stock and warrants continue to trade on the Nasdaq Capital Market under the symbols CELU and CELUW, respectively.
• Celularity has 60 calendar days, until June 17, 2024, to submit a plan to regain compliance to Nasdaq.
• If the plan is accepted, Celularity has 180 calendar days from the original due date of the 2023 Form 10-K, until October 14, 2024, to implement the plan.
• There is no guarantee that Celularity will regain compliance or maintain compliance with other Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's failure to meet filing deadlines and the risk of delisting. This indicates potential financial or operational issues and creates uncertainty for investors.

Positives

• Celularity's stock and warrants continue to trade on the Nasdaq Capital Market while the company works to regain compliance.
• The company has a 60-day period to submit a plan to regain compliance.

Negatives

• Celularity failed to file its 2023 annual report on time, indicating potential issues with financial reporting.
• The company received a formal notice from Nasdaq for non-compliance with listing rules.
• There is no assurance that Celularity will regain compliance or maintain compliance with other Nasdaq listing requirements.
• The company faces the risk of delisting from the Nasdaq Capital Market.

Risks

• Celularity faces the risk of being delisted from the Nasdaq Capital Market if it fails to regain compliance.
• The delay in filing the annual report may indicate underlying financial or operational issues.
• There is uncertainty regarding the company's ability to meet the deadlines set by Nasdaq.
• Failure to regain compliance could negatively impact investor confidence and the company's stock price.

Future Outlook

Celularity intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period. However, there can be no assurance that Celularity will regain compliance within the compliance period or maintain compliance with the other Nasdaq listing requirements.

Management Comments

• Celularity informed Nasdaq that it had not yet completed the preparation of the financial statements for the year ended December 31, 2023.
• Celularity intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period.

Industry Context

This announcement highlights the importance of timely financial reporting for publicly listed companies and the consequences of non-compliance with exchange listing rules. It is not uncommon for companies to face delisting risks due to late filings, but it can significantly impact investor confidence and the company's future.

Comparison to Industry Standards

• Many companies listed on the Nasdaq are required to file their annual reports within a specific timeframe, typically 90 days after the fiscal year end.
• Failure to meet these deadlines can lead to non-compliance notices and potential delisting, as seen with Celularity.
• Other companies that have faced similar issues include those with complex financial structures or those undergoing significant operational changes.
• Companies like iBio, Inc. and Titan Pharmaceuticals, Inc. have also faced delisting notices due to late filings, highlighting the importance of maintaining compliance with listing requirements.

Stakeholder Impact

• Shareholders face the risk of a decline in stock value due to the potential delisting.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's ability to meet its obligations.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Celularity must submit a plan to regain compliance to Nasdaq by June 17, 2024.
• Celularity must implement the plan by October 14, 2024, if accepted by Nasdaq.

Key Dates

Keywords

delisting, Nasdaq, compliance, Form 10-K, annual report, financial statements, CELU, CELUW